Phase IIb trial of edratide (hCDR1) in patients with systemic lupus erythematosus
Phase of Trial: Phase II
Latest Information Update: 21 Mar 2016
Price : $35 *
At a glance
- Drugs Edratide (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- 21 Mar 2016 According to a XTL Biopharmaceuticals media release, the trial design has been completed for this trial.
- 25 Jan 2016 According to XTL Biopharmaceuticals media release, the Company has received written guidance from the U.S. Food and Drug Administration (FDA) in response to a pre-investigational new drug (IND) meeting package regarding its upcoming IND filing for its drug candidate.Based on the FDA's response, XTL plans to file its IND.
- 25 Jan 2016 According to XTL Biopharmaceuticals media release, company plans to review with its Clinical Advisory Board as it finalizes the study protocol including doses and study duration.